NCT01749566View on ClinicalTrials.gov

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
HIV
Interventions
DRUG

maraviroc

Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing

Trial Locations (1)

30303

Grady Infectious Diseases Program, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT01749566 - Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women | Biotech Hunter | Biotech Hunter